# Passage BIO, Inc.: financial statements, quarterly

PASG · Nasdaq · CIK 1787297 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pasg.md) · [Financials](/companies/pasg/financials.md) · [Filings](/companies/pasg/filings.md) · [Insiders](/companies/pasg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pasg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [11.5](/filings/0001558370-25-007489.md) | [10.4](/filings/0001558370-25-011146.md) | [8.7](/filings/0001104659-25-109180.md) | [9.6 d](/filings/0001104659-26-022549.md) | [7.7](/filings/0001104659-26-058987.md) | [5.8](/filings/0001104659-26-093021.md) | [4.3](/filings/0001104659-25-109180.md) | [5.4 d](/filings/0001104659-26-022549.md) | [4.1](/filings/0001104659-26-058987.md) | [3.3](/filings/0001104659-26-093021.md) |
| Operating income | $m | [(28.7)](/filings/0001558370-24-015431.md) | [(18.4) d](/filings/0001558370-25-002101.md) | [(18.1)](/filings/0001558370-25-007489.md) | [(17.4)](/filings/0001558370-25-011146.md) | [(20.7)](/filings/0001104659-25-109180.md) | [(14.3) d](/filings/0001104659-26-022549.md) | [(16.5)](/filings/0001104659-26-058987.md) | [(10.3)](/filings/0001104659-26-093021.md) | [(8.7)](/filings/0001104659-25-109180.md) | [(13.8) d](/filings/0001104659-26-022549.md) | [(8.2)](/filings/0001104659-26-058987.md) | [(8.3)](/filings/0001104659-26-093021.md) |
| Net income | $m | [(27.1)](/filings/0001558370-24-015431.md) | [(16.8) d](/filings/0001558370-25-002101.md) | [(16.7)](/filings/0001558370-25-007489.md) | [(16.0)](/filings/0001558370-25-011146.md) | [(19.3)](/filings/0001104659-25-109180.md) | [(12.7) d](/filings/0001104659-26-022549.md) | [(15.4)](/filings/0001104659-26-058987.md) | [(9.4)](/filings/0001104659-26-093021.md) | [(7.7)](/filings/0001104659-25-109180.md) | [(13.0) d](/filings/0001104659-26-022549.md) | [(7.6)](/filings/0001104659-26-058987.md) | [(7.8)](/filings/0001104659-26-093021.md) |
| Diluted EPS | $ per share | [(0.49)](/filings/0001558370-24-015431.md) | not reported | [(0.30)](/filings/0001558370-25-007489.md) | [(5.09)](/filings/0001558370-25-011146.md) | [(6.15)](/filings/0001104659-25-109180.md) | not reported | [(4.87)](/filings/0001104659-26-058987.md) | [(2.96)](/filings/0001104659-26-093021.md) | [(2.44)](/filings/0001104659-25-109180.md) | not reported | [(2.36)](/filings/0001104659-26-058987.md) | [(2.44)](/filings/0001104659-26-093021.md) |
| Basic EPS | $ per share | [(0.49)](/filings/0001558370-24-015431.md) | not reported | [(0.30)](/filings/0001558370-25-007489.md) | [(5.09)](/filings/0001558370-25-011146.md) | [(6.15)](/filings/0001104659-25-109180.md) | not reported | [(4.87)](/filings/0001104659-26-058987.md) | [(2.96)](/filings/0001104659-26-093021.md) | [(2.44)](/filings/0001104659-25-109180.md) | not reported | [(2.36)](/filings/0001104659-26-058987.md) | [(2.44)](/filings/0001104659-26-093021.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.6](/filings/0001558370-23-018686.md) | [21.7](/filings/0001558370-25-002101.md) | [36.8](/filings/0001558370-24-008058.md) | [24.8](/filings/0001558370-24-011463.md) | [32.3](/filings/0001558370-24-015431.md) | [37.6](/filings/0001104659-26-022549.md) | [63.4](/filings/0001558370-25-007489.md) | [57.6](/filings/0001558370-25-011146.md) | [52.8](/filings/0001104659-25-109180.md) | [46.3](/filings/0001104659-26-093021.md) | [33.3](/filings/0001104659-26-058987.md) | [24.2](/filings/0001104659-26-093021.md) |
| Current assets | $m | [136](/filings/0001558370-23-018686.md) | [118](/filings/0001558370-25-002101.md) | [108](/filings/0001558370-24-008058.md) | [95.0](/filings/0001558370-24-011463.md) | [87.2](/filings/0001558370-24-015431.md) | [78.8](/filings/0001104659-26-022549.md) | [66.7](/filings/0001558370-25-007489.md) | [60.3](/filings/0001558370-25-011146.md) | [55.7](/filings/0001104659-25-109180.md) | [47.8](/filings/0001104659-26-093021.md) | [34.7](/filings/0001104659-26-058987.md) | [25.2](/filings/0001104659-26-093021.md) |
| Total assets | $m | [169](/filings/0001558370-23-018686.md) | [151](/filings/0001558370-25-002101.md) | [141](/filings/0001558370-24-008058.md) | [125](/filings/0001558370-24-011463.md) | [112](/filings/0001558370-24-015431.md) | [102](/filings/0001104659-26-022549.md) | [86.0](/filings/0001558370-25-007489.md) | [79.2](/filings/0001558370-25-011146.md) | [74.2](/filings/0001104659-25-109180.md) | [62.3](/filings/0001104659-26-093021.md) | [36.5](/filings/0001104659-26-058987.md) | [25.2](/filings/0001104659-26-093021.md) |
| Current liabilities | $m | [19.8](/filings/0001558370-23-018686.md) | [16.3](/filings/0001558370-25-002101.md) | [12.8](/filings/0001558370-24-008058.md) | [12.4](/filings/0001558370-24-011463.md) | [17.0](/filings/0001558370-24-015431.md) | [19.4](/filings/0001104659-26-022549.md) | [17.8](/filings/0001558370-25-007489.md) | [19.8](/filings/0001558370-25-011146.md) | [22.2](/filings/0001104659-25-109180.md) | [23.1](/filings/0001104659-26-093021.md) | [20.1](/filings/0001104659-26-058987.md) | [20.7](/filings/0001104659-26-093021.md) |
| Total liabilities | $m | [43.0](/filings/0001558370-23-018686.md) | [39.3](/filings/0001558370-25-002101.md) | [35.6](/filings/0001558370-24-008058.md) | [34.8](/filings/0001558370-24-011463.md) | [39.0](/filings/0001558370-24-015431.md) | [41.2](/filings/0001104659-26-022549.md) | [39.3](/filings/0001558370-25-007489.md) | [40.9](/filings/0001558370-25-011146.md) | [43.0](/filings/0001104659-25-109180.md) | [43.5](/filings/0001104659-26-093021.md) | [24.7](/filings/0001104659-26-058987.md) | [20.7](/filings/0001104659-26-093021.md) |
| Shareholders' equity | $m | [126](/filings/0001558370-24-015431.md) | [111](/filings/0001104659-26-022549.md) | [105](/filings/0001558370-25-011146.md) | [90.6](/filings/0001104659-25-109180.md) | [72.7](/filings/0001104659-25-109180.md) | [61.3](/filings/0001104659-26-093021.md) | [46.7](/filings/0001104659-26-093021.md) | [38.3](/filings/0001104659-26-093021.md) | [31.1](/filings/0001104659-25-109180.md) | [18.8](/filings/0001104659-26-093021.md) | [11.8](/filings/0001104659-26-093021.md) | [4.5](/filings/0001104659-26-093021.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.2) d](/filings/0001558370-24-015431.md) | [(19.5) d](/filings/0001558370-25-002101.md) | [(18.9)](/filings/0001558370-25-007489.md) | [(13.1) d](/filings/0001558370-25-011146.md) | [(7.4) d](/filings/0001104659-25-109180.md) | [(8.4) d](/filings/0001104659-26-022549.md) | [(13.8)](/filings/0001104659-26-058987.md) | [(6.3) d](/filings/0001104659-26-093021.md) | [(4.9) d](/filings/0001104659-25-109180.md) | [(6.5) d](/filings/0001104659-26-022549.md) | [(13.0)](/filings/0001104659-26-058987.md) | [(9.2) d](/filings/0001104659-26-093021.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.5](/filings/0001558370-23-018686.md) | [54.6](/filings/0001558370-24-008058.md) | [54.7](/filings/0001558370-24-011463.md) | [54.8](/filings/0001558370-24-015431.md) | [56.3](/filings/0001558370-25-007489.md) | [3.1](/filings/0001558370-25-011146.md) | [3.1](/filings/0001104659-25-109180.md) | [3.2](/filings/0001104659-26-058987.md) | [3.2](/filings/0001104659-26-093021.md) | [3.2](/filings/0001104659-25-109180.md) | [3.2](/filings/0001104659-26-058987.md) | [3.2](/filings/0001104659-26-093021.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,217,810 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001104659-26-093021.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.